Longevity Report · Week of September 26, 2026
GLP-1 organ data, aging clocks, protein reanalysis, muscle science, public-health bets
- GLP-1 Drugs Move Beyond Weight Loss to Kidney and Cancer OutcomesThe most common mistake right now is treating the GLP-1 cancer signal as if it were a kidney-trial result. A viral post from Dr. William Li claims GLP-1 drugs were associated with 30–50% lower colon cancer recurrence, al…
- Aging Clocks Enter Clinical Trials as Surrogate Endpoints, Validation Still LackingThe press version of the rentosertib story reads like a milestone: an experimental drug made patients roughly three years biologically younger in twelve weeks. The paper itself says something narrower. The gap between th…
- Protein Harm Claim Reanalysis Challenges Dietary Guidelines NarrativeLast week, we followed the 1.2–1.6 g/kg/day recommended protein range into the 2025–2030 Dietary Guidelines fight. This week, the story moves from the ceiling to the floor beneath it: the reanalysis that challenges the o…
- Muscle Aging Targets Beyond Exercise: Ultrasound, Inotodiol, Calcium, CreatineHere is the thing most people get wrong about muscle aging: they assume the problem is the muscle.
- National Healthy-Longevity Bets: NHS Predictive AI and Singapore ClinicBritain and Singapore have made opposite bets on the same problem. One has trained a generative AI on the medical histories of 57 million people and published no clinical outcomes from it. The other has opened a public h…
Threads we are following
- Whether peer-reviewed GLP-1 trials replicate the claimed 30-50% lower colon cancer recurrence and fewer metastases.
- Whether any aging clock can be validated as a surrogate endpoint that predicts clinical benefit, not just biomarker movement.
- Whether the 2025–2030 Dietary Guidelines committee addresses the reanalysis in its final protein recommendations.
- Whether abdominal LIPUS can translate from aged mice to human sarcopenia trials.
- Whether NHS Foresight publishes retrospective validation metrics or clinical outcome data.
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.